NCT03460977 2026-03-13A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaPfizerPhase 1 Recruiting453 enrolled
NCT04067336 2025-11-10First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1/2 Recruiting263 enrolled 1 FDA